Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients-Reference-Cited by-同舟云学术

Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients

Published:2020-12-16 Issue:1 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Teaford Hilary R.¹^ORCID,Stevens Ryan W.¹,Rule Andrew D.²³,Mara Kristin C.⁴,Kashani Kianoush B.²⁵,Lieske John C.²⁶,O’Horo John⁵⁷,Barreto Erin F.¹⁸^ORCID

Affiliation:

1. Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA

2. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA

3. Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA

4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA

5. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA

6. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

7. Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA

8. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA

Abstract

The use of the kidney function biomarker cystatin C (cysC) can improve the accuracy of vancomycin dosing for target trough attainment in nonobese patients. It is unknown whether cysC can also improve vancomycin target trough attainment in overweight and obese patients. We conducted a retrospective observational study of overweight or obese hospitalized adults with stable renal function administered intravenous vancomycin between January 2011 and July 2019. Linear regression models were used to predict initial steady-state vancomycin troughs using several factors, including various cysC- and serum creatinine (SCr)-based estimates of kidney function.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01487-20

Reference31 articles.

1. Prevalence of obesity among adults and youth: United States, 2015–2016 key findings data from the National Health and Nutrition Examination Survey;Hales CM;NCHS Data Brief,2017

2. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years

3. Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies

4. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists

5. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum and urinary biomarkers of vancomycin-induced acute kidney injury: A prospective, observational analysis;Medicine;2024-08-09

2. Contemporary considerations for nephrotoxin stewardship: Estimating kidney function and use of novel biomarkers;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2024-07-03

3. Pharmacokinetics of obese adults: Not only an increase in weight;Biomedicine & Pharmacotherapy;2023-10

4. Medication-Related Adverse Events and Discordancies in Cystatin C–Based vs Serum Creatinine–Based Estimated Glomerular Filtration Rate in Patients With Cancer;JAMA Network Open;2023-07-05

5. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-02-18